Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning.
Read More
The effectiveness of melanoma treatment could be boosted if combined with a well-known drug for rheumatoid arthritis (RA), indicates early UK research.
Read More
Germany’s Merck has linked with Array BioPharma and Pierre Fabre to initiate a lage-stage trial assessing the efficacy of a new combination therapy in BRAF-mutant metastatic colorectal cancer.
Read More
